Investor profile
Versant Ventures has backed 6 European tech companies across 8 funding rounds between 2014 and 2024, joining rounds totalling €385M. Most active in Healthtech. Data as of 7 Aug 2026.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| T-knife | Germany | 1 | €93M |
| CRISPR Therapeutics | Switzerland | 2 | €82M |
| Antag Therapeutics | Denmark | 1 | €80M |
| Nouscom | Switzerland | 2 | €54M |
| Cimeio Therapeutics | Switzerland |
| Company | Stage | Amount | Date |
|---|---|---|---|
| T-knife | Series B | €93M | 2021-08 |
| Antag Therapeutics | Series A | €80M | 2024-12 |
| CRISPR Therapeutics | Series B | €59M | 2015-04 |
| Cimeio Therapeutics |
| 1 |
| €46M |
| Enterprise Therapeutics | UK | 1 | €30M |
| Series A |
| €46M |
| 2022-04 |
| Nouscom | Series B | €42M | 2017-11 |
| Enterprise Therapeutics | Series B | €30M | 2024-01 |
| CRISPR Therapeutics | Series A | €23M | 2014-04 |
| Nouscom | Series A | €12M | 2016-05 |
